Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PYTX-004 + anti-PD-1
- Development stage
- Preclinical
- Lead developer
- Papyrus Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PYTX-004 + anti-PD-1 is a preclinical-stage combination therapy being developed by Papyrus Therapeutics for the treatment of solid tumors, with a particular focus on ovarian cancer. The combination consists of PYTX-004, a recombinant Fc-fusion protein (OPCML-Fc) designed to restore the function of the Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML) tumor suppressor, and an anti-PD-1 checkpoint inhibitor. OPCML is a cell-surface protein that is frequently epigenetically silenced in various cancers; when restored, it acts as a broadly acting tumor suppressor by binding and inactivating nine activated receptor tyrosine kinases (RTKs), including HER2, HER4, FGFR1, FGFR3, EphA2, AXL, TYRO3, MET, and VEGFR3. By combining this multi-RTK inhibition and direct oncolysis with the immune-stimulating effects of PD-1 blockade, the therapy aims to achieve synergistic anti-tumor activity, suppress angiogenesis, and activate robust anti-tumor immunity.
- Other names
- PYTX-004 + immuno-oncologyPYTX-004 + anti-PD-1 checkpoint inhibitor
02
Targets
AXL (AXL receptor tyrosine kinase)EPHA2 (Ephrin type-A receptor 2)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFR4 (Vascular endothelial growth factor Receptor-3)OPCML (Opioid binding protein/cell adhesion molecule-like)
Beyond the preview
Go deeper on PYTX-004 + anti-PD-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PYTX-004 + anti-PD-1.